17353198	207	Ji Z	Oncogenic KRAS activates hedgehog signaling pathway in pancreatic cancer cells.	The Journal of biological chemistry	2007	98
19088048	207	Solit DB	Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma.	Clinical cancer research 	2008	68
19487299	207	Ricarte-Filho JC	Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1.	Cancer research	2009	123
19996208	207	Davies MA	Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma.	Clinical cancer research 	2009	62
21216929	207	Janku F	PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.	Molecular cancer therapeutics	2011	127
22194965	207	Atefi M	Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway.	PloS one	2011	63
22205714	207	Su F	Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation.	Cancer research	2012	51
22261800	207	Shimizu T	The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer.	Clinical cancer research 	2012	110
23444215	207	Catalanotti F	Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma.	Clinical cancer research 	2013	36
23897969	207	Iyer G	Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer.	Journal of clinical oncology 	2013	58
24265152	207	Shi H	A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.	Cancer discovery	2014	46
26014291	207	Meric-Bernstam F	Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials.	Journal of clinical oncology 	2015	51
24569458	369	Imielinski M	Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma.	The Journal of clinical investigation	2014	28
24652991	369	Nelson DS	Somatic activating ARAF mutations in Langerhans cell histiocytosis.	Blood	2014	28
12068308	673	Davies H	Mutations of the BRAF gene in human cancer.	Nature	2002	2004
12198537	673	Rajagopalan H	Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status.	Nature	2002	276
12460918	673	Brose MS	BRAF and RAS mutations in human lung cancer and melanoma.	Cancer research	2002	256
12697856	673	Cohen Y	BRAF mutation in papillary thyroid carcinoma.	Journal of the National Cancer Institute	2003	149
12970315	673	Namba H	Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers.	The Journal of clinical endocrinology and metabolism	2003	78
14500344	673	Hingorani SR	Suppression of BRAF(V599E) in human melanoma abrogates transformation.	Cancer research	2003	105
14679157	673	Maldonado JL	Determinants of BRAF mutations in primary melanomas.	Journal of the National Cancer Institute	2003	104
15488754	673	Garnett MJ	Guilty as charged: B-RAF is a human oncogene.	Cancer cell	2004	156
16174717	673	Xing M	BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer.	The Journal of clinical endocrinology and metabolism	2005	147
16804544	673	Weisenberger DJ	CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer.	Nature genetics	2006	534
17148775	673	Samowitz WS	Association of smoking, CpG island methylator phenotype, and V600E BRAF mutations in colon cancer.	Journal of the National Cancer Institute	2006	105
17717450	673	Kebebew E	The prevalence and prognostic value of BRAF mutation in thyroid cancer.	Annals of surgery	2007	69
17724477	673	Michaloglou C	BRAF(E600) in benign and malignant human tumours.	Oncogene	2008	71
17785355	673	Lupi C	Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma.	The Journal of clinical endocrinology and metabolism	2007	60
17940185	673	Xing M	BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications.	Endocrine reviews	2007	186
18287029	673	Tsai J	Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity.	Proceedings of the National Academy of Sciences of the United States of America	2008	331
18310287	673	Frasca F	BRAF(V600E) mutation and the biology of papillary thyroid cancer.	Endocrine-related cancer	2008	54
18398503	673	Pfister S	BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas.	The Journal of clinical investigation	2008	112
18519771	673	French AJ	Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer.	Clinical cancer research 	2008	71
18532874	673	Viros A	Improving melanoma classification by integrating genetic and morphologic features.	PLoS medicine	2008	59
18682506	673	Elisei R	BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study.	The Journal of clinical endocrinology and metabolism	2008	92
18832519	673	Ogino S	CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer.	Gut	2009	259
19255327	673	Kloos RT	Phase II trial of sorafenib in metastatic thyroid cancer.	Journal of clinical oncology 	2009	123
19276360	673	Hoeflich KP	Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.	Cancer research	2009	50
19414674	673	Xing M	BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer.	Journal of clinical oncology 	2009	47
19861538	673	Riesco-Eizaguirre G	The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer.	Cancer research	2009	48
19883729	673	Xing M	Prognostic utility of BRAF mutation in papillary thyroid cancer.	Molecular and cellular endocrinology	2010	41
19924296	673	MacConaill LE	Profiling critical cancer gene mutations in clinical tumor samples.	PloS one	2009	145
20519626	673	Badalian-Very G	Recurrent BRAF mutations in Langerhans cell histiocytosis.	Blood	2010	108
20551065	673	Yang H	RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models.	Cancer research	2010	102
20587792	673	Limsui D	Cigarette smoking and colorectal cancer risk by molecularly defined subtypes.	Journal of the National Cancer Institute	2010	88
20630094	673	Rubinstein JC	Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032.	Journal of translational medicine	2010	60
20635392	673	Tie J	Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation.	International journal of cancer	2011	39
20818844	673	Flaherty KT	Inhibition of mutated, activated BRAF in metastatic melanoma.	The New England journal of medicine	2010	938
20823850	673	Bollag G	Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.	Nature	2010	428
20959481	673	Gopal YN	Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells.	Cancer research	2010	96
21139585	673	Arkenau HT	Targeting BRAF for patients with melanoma.	British journal of cancer	2011	36
21274720	673	Schindler G	Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma.	Acta neuropathologica	2011	134
21285991	673	Yokota T	BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer.	British journal of cancer	2011	79
21343559	673	Long GV	Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.	Journal of clinical oncology 	2011	163
21430775	673	Chapman MA	Initial genome sequencing and analysis of multiple myeloma.	Nature	2011	414
21456008	673	Tran B	Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer.	Cancer	2011	92
21479234	673	Dias-Santagata D	BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications.	PloS one	2011	57
21639808	673	Chapman PB	Improved survival with vemurafenib in melanoma with BRAF V600E mutation.	The New England journal of medicine	2011	1498
21663470	673	Tiacci E	BRAF mutations in hairy-cell leukemia.	The New England journal of medicine	2011	157
21768580	673	Ladabaum U	Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis.	Annals of internal medicine	2011	71
21882184	673	Kim TH	The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis.	Cancer	2012	60
22012135	673	Capper D	Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases.	Acta neuropathologica	2012	40
22038996	673	Nicolaides TP	Targeted therapy for BRAFV600E malignant astrocytoma.	Clinical cancer research 	2011	51
22105174	673	Chakravarty D	Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation.	The Journal of clinical investigation	2011	59
22147942	673	Ogino S	Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803.	Clinical cancer research 	2012	80
22180495	673	Yang H	Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.	Cancer research	2012	54
22228154	673	Kalady MF	BRAF mutations in colorectal cancer are associated with distinct clinical characteristics and worse prognosis.	Diseases of the colon and rectum	2012	38
22235286	673	Yancovitz M	Intra- and inter-tumor heterogeneity of BRAF(V600E))mutations in primary and metastatic melanoma.	PloS one	2012	59
22306669	673	Halait H	Analytical performance of a real-time PCR-based assay for V600 mutations in the BRAF gene, used as the companion diagnostic test for the novel BRAF inhibitor vemurafenib in metastatic melanoma.	Diagnostic molecular pathology 	2012	35
22332713	673	Anderson S	Multisite analytic performance studies of a real-time polymerase chain reaction assay for the detection of BRAF V600E mutations in formalin-fixed, paraffin-embedded tissue specimens of malignant melanoma.	Archives of pathology and laboratory medicine	2012	37
22355009	673	Hong DS	BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency.	Clinical cancer research 	2012	36
22356324	673	Sosman JA	Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.	The New England journal of medicine	2012	474
22393095	673	Popovici V	Identification of a poor-prognosis BRAF-mutant-like population of patients with colon cancer.	Journal of clinical oncology 	2012	47
22395615	673	Shi H	Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance.	Nature communications	2012	160
22454415	673	McArthur GA	Marked, homogeneous, and early 18Ffluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma.	Journal of clinical oncology 	2012	33
22508706	673	Guerra A	A high percentage of BRAFV600E alleles in papillary thyroid carcinoma predicts a poorer outcome.	The Journal of clinical endocrinology and metabolism	2012	30
22535154	673	Menzies AM	Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma.	Clinical cancer research 	2012	64
22608338	673	Falchook GS	Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.	Lancet	2012	179
22640478	673	Ascierto PA	Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use.	Journal of translational medicine	2012	30
22649091	673	Sen B	Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib.	Science translational medicine	2012	34
22743296	673	Gautschi O	A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib.	Journal of thoracic oncology 	2012	37
22798288	673	Dahlman KB	BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.	Cancer discovery	2012	49
22859608	673	Sahm F	BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis.	Blood	2012	34
22879539	673	Haroche J	High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses.	Blood	2012	74
22899730	673	Phipps AI	BRAF mutation status and survival after colorectal cancer diagnosis according to patient and tumor characteristics.	Cancer epidemiology, biomarkers and prevention 	2012	40
22930283	673	Grisham RN	BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer.	Cancer	2013	27
22932786	673	Tufano RP	BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis.	Medicine	2012	46
22941165	673	Howell GM	BRAF V600E mutation independently predicts central compartment lymph node metastasis in patients with papillary thyroid cancer.	Annals of surgical oncology	2013	27
22972589	673	Patel SP	Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma.	Cancer	2013	28
23026937	673	Long GV	Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma.	The American journal of surgical pathology	2013	46
23055546	673	Li C	BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis.	The Journal of clinical endocrinology and metabolism	2012	36
23056577	673	Safaee Ardekani G	The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis.	PloS one	2012	34
23066120	673	Elisei R	The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study.	The Journal of clinical endocrinology and metabolism	2012	34
23258922	673	Haroche J	Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation.	Blood	2013	74
23273605	673	Greaves WO	Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma.	The Journal of molecular diagnostics 	2013	37
23290787	673	Sullivan RJ	Resistance to BRAF-targeted therapy in melanoma.	European journal of cancer	2013	74
23416974	673	Kwong LN	Targeted therapy for melanoma: rational combinatorial approaches.	Oncogene	2014	23
23442159	673	Chappé C	Dysembryoplastic neuroepithelial tumors share with pleomorphic xanthoastrocytomas and gangliogliomas BRAF(V600E) mutation and expression.	Brain pathology	2013	26
23533272	673	Sievert AJ	Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas.	Proceedings of the National Academy of Sciences of the United States of America	2013	52
23569304	673	Trunzer K	Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.	Journal of clinical oncology 	2013	83
23571588	673	Xing M	Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer.	JAMA	2013	123
23612012	673	Andrulis M	Targeting the BRAF V600E mutation in multiple myeloma.	Cancer discovery	2013	35
23735514	673	Robert C	Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.	The Lancet. Oncology	2013	36
23800934	673	Nishihara R	Aspirin use and risk of colorectal cancer according to BRAF mutation status.	JAMA	2013	48
23833299	673	Nathanson KL	Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436).	Clinical cancer research 	2013	36
23852808	673	Roepman P	Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition.	International journal of cancer	2014	47
23856246	673	Abaan OD	The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.	Cancer research	2013	80
23878352	673	Lochhead P	Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication.	Journal of the National Cancer Institute	2013	81
23903755	673	Corcoran RB	TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma.	Science translational medicine	2013	49
23918947	673	Ascierto PA	Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma.	Journal of clinical oncology 	2013	60
24291778	673	Bucheit AD	Emerging insights into resistance to BRAF inhibitors in melanoma.	Biochemical pharmacology	2014	29
24295639	673	Dummer R	Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study.	European journal of cancer	2014	36
24345920	673	Hutchinson KE	BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition.	Clinical cancer research 	2013	33
24410877	673	Ihle MA	Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations.	BMC cancer	2014	46
24463458	673	Rizos H	BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact.	Clinical cancer research 	2014	63
24508103	673	McArthur GA	Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.	The Lancet. Oncology	2014	119
24582505	673	Larkin J	Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.	The Lancet. Oncology	2014	28
24617711	673	Liu X	TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer.	The Journal of clinical endocrinology and metabolism	2014	41
24638167	673	Berres ML	BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups.	The Journal of experimental medicine	2014	42
24671772	673	Cangi MG	BRAFV600E-mutation is invariably present and associated to oncogene-induced senescence in Erdheim-Chester disease.	Annals of the rheumatic diseases	2015	17
24725538	673	Robinson GW	Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy.	BMC cancer	2014	24
24737664	673	Yaeger R	BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer.	Cancer	2014	29
24768112	673	Brose MS	Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.	Lancet	2014	112
24958825	673	Hu-Lieskovan S	Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges.	Journal of clinical oncology 	2014	41
25024077	673	Xing M	BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence.	Journal of clinical oncology 	2014	57
25139339	673	Venderbosch S	Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies.	Clinical cancer research 	2014	23
25332244	673	Xing M	Association between BRAF V600E mutation and recurrence of papillary thyroid cancer.	Journal of clinical oncology 	2015	48
25344914	673	Spagnolo F	Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma.	Oncotarget	2014	28
25353071	673	Dadu R	Efficacy and tolerability of vemurafenib in patients with BRAF(V600E) -positive papillary thyroid cancer: M.D. Anderson Cancer Center off label experience.	The Journal of clinical endocrinology and metabolism	2015	17
25411185	673	Sanmamed MF	Quantitative cell-free circulating BRAFV600E mutation analysis by use of droplet digital PCR in the follow-up of patients with melanoma being treated with BRAF inhibitors.	Clinical chemistry	2015	23
25422482	673	Haroche J	Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease.	Journal of clinical oncology 	2015	28
25891304	673	Postow MA	Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.	The New England journal of medicine	2015	330
25918280	673	Fakih MG	Metastatic colorectal cancer: current state and future directions.	Journal of clinical oncology 	2015	33
26037941	673	Long GV	Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial.	Lancet	2015	84
26038390	673	Campbell PT	Association between body mass index and mortality for colorectal cancer survivors: overall and by tumor molecular phenotype.	Cancer epidemiology, biomarkers and prevention 	2015	16
26287849	673	Hyman DM	Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.	The New England journal of medicine	2015	128
26338525	673	Cremolini C	FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.	The Lancet. Oncology	2015	39
26527776	673	André T	Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.	Journal of clinical oncology 	2015	20
26715644	673	Girotti MR	Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma.	Cancer discovery	2016	16
26733501	673	Liu R	TERT promoter mutations in thyroid cancer.	Endocrine-related cancer	2016	13
26811525	673	Long GV	Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib.	Journal of clinical oncology 	2016	21
27022117	673	Stadler ZK	Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing Panels.	Journal of clinical oncology 	2016	18
27080216	673	Planchard D	Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial.	The Lancet. Oncology	2016	18
18790768	1019	Smalley KS	Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas.	Molecular cancer therapeutics	2008	64
20507599	1026	Baba Y	Epigenomic diversity of colorectal cancer indicated by LINE-1 methylation in a database of 869 tumors.	Molecular cancer	2010	50
26551667	1027	da Silva Almeida AC	The mutational landscape of cutaneous T cell lymphoma and Sézary syndrome.	Nature genetics	2015	27
16964246	1029	Denoyelle C	Anti-oncogenic role of the endoplasmic reticulum differentially activated by mutations in the MAPK pathway.	Nature cell biology	2006	97
17065427	1029	Ogino S	CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations.	The Journal of molecular diagnostics 	2006	134
17088437	1029	Ikediobi ON	Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.	Molecular cancer therapeutics	2006	152
18922929	1029	Barault L	Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases.	Cancer research	2008	106
19593635	1029	Hollestelle A	Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines.	Breast cancer research and treatment	2010	83
19825961	1029	Ogino S	Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype.	Clinical cancer research 	2009	92
20068183	1029	Schiffman JD	Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas.	Cancer research	2010	86
20460471	1029	Jönsson G	Gene expression profiling-based identification of molecular subtypes in stage IV melanomas with different clinical outcome.	Clinical cancer research 	2010	58
21509761	1029	Ahn JB	DNA methylation predicts recurrence from resected stage III proximal colon cancer.	Cancer	2011	47
21636552	1029	Raabe EH	BRAF activation induces transformation and then senescence in human neural stem cells: a pilocytic astrocytoma model.	Clinical cancer research 	2011	42
22067401	1029	Oberholzer PA	RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors.	Journal of clinical oncology 	2012	79
22256804	1029	Su F	RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.	The New England journal of medicine	2012	200
23907151	1029	Kanagal-Shamanna R	Next-generation sequencing-based multi-gene mutation profiling of solid tumors using fine needle aspiration samples: promises and challenges for routine clinical diagnostics.	Modern pathology 	2014	32
25584893	1029	Damsky W	mTORC1 activation blocks BrafV600E-induced growth arrest but is insufficient for melanoma formation.	Cancer cell	2015	15
25589618	1029	Li YY	Genomic analysis of metastatic cutaneous squamous cell carcinoma.	Clinical cancer research 	2015	17
20664940	1045	Minoo P	Characterization of rectal, proximal and distal colon cancers based on clinicopathological, molecular and protein profiles.	International journal of oncology	2010	51
24764661	1045	Kim JH	Molecular and prognostic heterogeneity of microsatellite-unstable colorectal cancer.	World journal of gastroenterology	2014	21
24548766	1048	Yang CY	Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes.	European journal of cancer	2014	58
21107320	1326	Johannessen CM	COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.	Nature	2010	413
22554099	1493	Ascierto PA	The role of BRAF V600 mutation in melanoma.	Journal of translational medicine	2012	56
24054424	1493	Eggermont AM	Cutaneous melanoma.	Lancet	2014	64
25795410	1493	Weber JS	Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.	The Lancet. Oncology	2015	227
27622997	1493	Hodi FS	Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.	The Lancet. Oncology	2016	31
15761464	1499	Bell DA	Origins and molecular pathology of ovarian cancer.	Modern pathology 	2005	100
21521850	1499	Morikawa T	Association of CTNNB1 (beta-catenin) alterations, body mass index, and physical activity with survival in patients with colorectal cancer.	JAMA	2011	78
22142829	1499	Shukla N	Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways.	Clinical cancer research 	2012	62
22234612	1499	Biechele TL	Wnt/β-catenin signaling and AXIN1 regulate apoptosis triggered by inhibition of the mutant kinase BRAFV600E in human melanoma.	Science signaling	2012	50
22536370	1499	Lovly CM	Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials.	PloS one	2012	49
22538770	1499	Santarpia L	Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers.	Breast cancer research and treatment	2012	35
22653804	1499	McConechy MK	Use of mutation profiles to refine the classification of endometrial carcinomas.	The Journal of pathology	2012	45
22975805	1499	Seo JS	The transcriptional landscape and mutational profile of lung adenocarcinoma.	Genome research	2012	139
23325582	1499	Peeters M	Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer.	Clinical cancer research 	2013	56
23979959	1499	Nikiforova MN	Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer.	The Journal of clinical endocrinology and metabolism	2013	52
24413733	1499	Brastianos PK	Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas.	Nature genetics	2014	36
25720322	1499	Stelloo E	Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative.	Modern pathology 	2015	16
22735384	1731	Hauschild A	Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.	Lancet	2012	486
15863375	1956	Moroni M	Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study.	The Lancet. Oncology	2005	197
16231326	1956	Shigematsu H	Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers.	International journal of cancer	2006	139
17075123	1956	Hirsch FR	Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer.	Journal of clinical oncology 	2006	145
18339877	1956	Jhawer M	PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab.	Cancer research	2008	130
19010912	1956	Pratilas CA	Genetic predictors of MEK dependence in non-small cell lung cancer.	Cancer research	2008	83
19536109	1956	Walther A	Genetic prognostic and predictive markers in colorectal cancer.	Nature reviews. Cancer	2009	170
19584155	1956	Schmid K	EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases.	Clinical cancer research 	2009	66
19738166	1956	Siena S	Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer.	Journal of the National Cancer Institute	2009	144
19806185	1956	Sartore-Bianchi A	Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer.	PloS one	2009	85
19826477	1956	Soh J	Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells.	PloS one	2009	66
19884556	1956	Laurent-Puig P	Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.	Journal of clinical oncology 	2009	189
19942479	1956	Folprecht G	Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.	The Lancet. Oncology	2010	131
20100961	1956	Bardelli A	Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer.	Journal of clinical oncology 	2010	160
20103678	1956	Baldus SE	Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases.	Clinical cancer research 	2010	109
20855837	1956	Sun Y	Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.	Journal of clinical oncology 	2010	93
21163703	1956	De Roock W	KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer.	The Lancet. Oncology	2011	125
21277552	1956	Pao W	New driver mutations in non-small-cell lung cancer.	The Lancet. Oncology	2011	244
21408138	1956	van Eijk R	Rapid KRAS, EGFR, BRAF and PIK3CA mutation analysis of fine needle aspirates from non-small-cell lung cancer using allele-specific qPCR.	PloS one	2011	43
21483012	1956	Paik PK	Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations.	Journal of clinical oncology 	2011	115
21502544	1956	Van Cutsem E	Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.	Journal of clinical oncology 	2011	350
21641636	1956	Maughan TS	Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.	Lancet	2011	199
21646616	1956	Price TJ	Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer.	Journal of clinical oncology 	2011	58
22135231	1956	Chaft JE	Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling.	Molecular cancer therapeutics	2012	55
22140546	1956	Li C	Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers.	PloS one	2011	54
22178589	1956	Andersen JB	Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors.	Gastroenterology	2012	76
22228640	1956	Rekhtman N	Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations.	Clinical cancer research 	2012	73
22317764	1956	Zhang Y	Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis.	Clinical cancer research 	2012	46
22448344	1956	Corcoran RB	EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.	Cancer discovery	2012	179
22722843	1956	Diaz LA Jr	The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers.	Nature	2012	379
22768234	1956	An SJ	Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status.	PloS one	2012	50
22773810	1956	Ohashi K	Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1.	Proceedings of the National Academy of Sciences of the United States of America	2012	121
23021375	1956	Berg M	EGFR and downstream genetic alterations in KRAS/BRAF and PI3K/AKT pathways in colorectal cancer: implications for targeted therapy.	Discovery medicine	2012	32
23136247	1956	Gasch C	Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer.	Clinical chemistry	2013	55
23233388	1956	Mostert B	KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue.	International journal of cancer	2013	30
23242808	1956	Girotti MR	Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma.	Cancer discovery	2013	99
23362162	1956	Tuononen K	Comparison of targeted next-generation sequencing (NGS) and real-time PCR in the detection of EGFR, KRAS, and BRAF mutations on formalin-fixed, paraffin-embedded tumor material of non-small cell lung carcinoma-superiority of NGS.	Genes, chromosomes and cancer	2013	34
23391413	1956	Voss JS	Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions.	Human pathology	2013	38
23470965	1956	Yu HA	Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.	Clinical cancer research 	2013	251
23723294	1956	Dearden S	Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap).	Annals of oncology 	2013	58
23833300	1956	Cardarella S	Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer.	Clinical cancer research 	2013	34
24236184	1956	Scarpa A	Molecular typing of lung adenocarcinoma on cytological samples using a multigene next generation sequencing panel.	PloS one	2013	28
24429876	1956	Oxnard GR	Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA.	Clinical cancer research 	2014	111
24666267	1956	Therkildsen C	The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.	Acta oncologica	2014	56
24670642	1956	Sun C	Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.	Nature	2014	139
24743704	1956	Li S	Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts.	British journal of cancer	2014	25
24846037	1956	Kris MG	Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.	JAMA	2014	182
24857124	1956	Gerber DE	Management and future directions in non-small cell lung cancer with known activating mutations.	American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Meeting	2014	23
25013125	1956	Couraud S	Noninvasive diagnosis of actionable mutations by deep sequencing of circulating free DNA in lung cancer from never-smokers: a proof-of-concept study from BioCAST/IFCT-1002.	Clinical cancer research 	2014	40
25057166	1956	Missiaglia E	Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features.	Annals of oncology 	2014	38
25164765	1956	Brannon AR	Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions.	Genome biology	2014	54
25248381	1956	Laurent-Puig P	Clinical relevance of KRAS-mutated subclones detected with picodroplet digital PCR in advanced colorectal cancer treated with anti-EGFR therapy.	Clinical cancer research 	2015	30
25345567	1956	Hagemann IS	Clinical next-generation sequencing in patients with non-small cell lung cancer.	Cancer	2015	29
25468223	1956	Cohen AL	Glioma biology and molecular markers.	Cancer treatment and research	2015	26
25567908	1956	Drilon A	Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches.	Clinical cancer research 	2015	30
25593032	1956	Linnekamp JF	Colorectal cancer heterogeneity and targeted therapy: a case for molecular disease subtypes.	Cancer research	2015	21
25623215	1956	Arena S	Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer.	Clinical cancer research 	2015	24
25628445	1956	Morelli MP	Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment.	Annals of oncology 	2015	22
25629635	1956	Wu C	High Discrepancy of Driver Mutations in Patients with NSCLC and Synchronous Multiple Lung Ground-Glass Nodules.	Journal of thoracic oncology 	2015	16
25639985	1956	Mao C	Concordant analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal cancer and matched metastases.	Scientific reports	2015	19
25667274	1956	Lopez-Chavez A	Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial.	Journal of clinical oncology 	2015	33
25673558	1956	Pietrantonio F	Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis.	European journal of cancer	2015	37
25673644	1956	Ahronian LG	Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.	Cancer discovery	2015	46
25738220	1956	Sholl LM	Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience.	Journal of thoracic oncology 	2015	37
25989278	1956	Rowland A	Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer.	British journal of cancer	2015	21
26243863	1956	Kavuri SM	HER2 activating mutations are targets for colorectal cancer treatment.	Cancer discovery	2015	18
26318427	1956	Bronte G	New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?	Oncotarget	2015	16
26354927	1956	Dubbink HJ	Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial.	Neuro-oncology	2016	14
26358176	1956	Dietel M	A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.	Cancer gene therapy	2015	25
26460303	1956	Kopetz S	Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer.	Journal of clinical oncology 	2015	41
26690310	1956	Richman SD	HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials.	The Journal of pathology	2016	11
26777916	1956	Barlesi F	Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT).	Lancet	2016	43
26942675	1956	Li X	Mitochondria-Translocated PGK1 Functions as a Protein Kinase to Coordinate Glycolysis and the TCA Cycle in Tumorigenesis.	Molecular cell	2016	14
27060149	1956	Lai Z	VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research.	Nucleic acids research	2016	12
27922044	1956	Punt CJ	From tumour heterogeneity to advances in precision treatment of colorectal cancer.	Nature reviews. Clinical oncology	2017	5
22761469	2064	Arcila ME	Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas.	Clinical cancer research 	2012	53
23159108	2064	Colomba E	Detection of BRAF p.V600E mutations in melanomas: comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing.	The Journal of molecular diagnostics 	2013	36
24327398	2120	Leeman-Neill RJ	ETV6-NTRK3 is a common chromosomal rearrangement in radiation-associated thyroid cancer.	Cancer	2014	25
26810070	2130	Qaddoumi I	Genetic alterations in uncommon low-grade neuroepithelial tumors: BRAF, FGFR1, and MYB mutations occur at high frequency and align with morphology.	Acta neuropathologica	2016	15
22730329	2261	Yadav V	Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma.	The Journal of biological chemistry	2012	47
25608663	2263	Sia D	Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma.	Nature communications	2015	29
21998291	2475	Wallin JJ	GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway.	Molecular cancer therapeutics	2011	64
23549875	2475	Coffee EM	Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer.	Clinical cancer research 	2013	28
24055054	2475	Villanueva J	Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma.	Cell reports	2013	43
24569374	2475	Ma XH	Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma.	The Journal of clinical investigation	2014	77
22261812	2776	Minor DR	Sunitinib therapy for melanoma patients with KIT mutations.	Clinical cancer research 	2012	33
17942460	2956	Imai K	Carcinogenesis and microsatellite instability: the interrelationship between genetics and epigenetics.	Carcinogenesis	2008	71
25305506	2956	Sinicrope FA	Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes.	Gastroenterology	2015	42
22763439	3082	Straussman R	Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion.	Nature	2012	413
15188009	3265	Bamford S	The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website.	British journal of cancer	2004	351
21325462	3265	Moura MM	High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas.	The Journal of clinical endocrinology and metabolism	2011	37
22241789	3265	Hayes DN	Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements.	Clinical cancer research 	2012	36
26276366	3265	Nishida T	The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines.	Gastric cancer 	2016	18
16322212	3320	da Rocha Dias S	Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin.	Cancer research	2005	69
24398428	3320	Acquaviva J	Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.	Molecular cancer therapeutics	2014	28
22180306	3417	Borger DR	Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping.	The oncologist	2012	126
23369684	3558	Jang S	Which drug, and when, for patients with BRAF-mutant melanoma?	The Lancet. Oncology	2013	45
16801397	3569	Sumimoto H	The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells.	The Journal of experimental medicine	2006	128
18980976	3815	Beadling C	KIT gene mutations and copy number in melanoma subtypes.	Clinical cancer research 	2008	104
26091043	3815	Cancer Genome Atlas Network.	Genomic Classification of Cutaneous Melanoma.	Cell	2015	197
16618717	3845	Lièvre A	KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.	Cancer research	2006	491
17101316	3845	Spring KJ	High prevalence of sessile serrated adenomas with BRAF mutations: a prospective study of patients undergoing colonoscopy.	Gastroenterology	2006	82
18224685	3845	Barault L	Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers.	International journal of cancer	2008	84
18669866	3845	Perrone F	PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients.	Annals of oncology 	2009	112
19001320	3845	Di Nicolantonio F	Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.	Journal of clinical oncology 	2008	416
19237633	3845	Ogino S	PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer.	Journal of clinical oncology 	2009	111
19401449	3845	Wee S	PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers.	Cancer research	2009	116
19603018	3845	Loupakis F	KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.	British journal of cancer	2009	136
19603024	3845	Souglakos J	Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer.	British journal of cancer	2009	76
19661383	3845	Yun J	Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells.	Science	2009	210
19686742	3845	Nosho K	A prospective cohort study shows unique epigenetic, genetic, and prognostic features of synchronous colorectal cancers.	Gastroenterology	2009	53
19884549	3845	Richman SD	KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial.	Journal of clinical oncology 	2009	146
19908233	3845	Zlobec I	Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis.	International journal of cancer	2010	58
20008640	3845	Roth AD	Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.	Journal of clinical oncology 	2010	282
20102720	3845	Goel A	Aberrant DNA methylation in hereditary nonpolyposis colorectal cancer without mismatch repair deficiency.	Gastroenterology	2010	42
20413299	3845	Tol J	Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.	European journal of cancer	2010	61
20501503	3845	Fariña-Sarasqueta A	The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients.	Annals of oncology 	2010	72
20619739	3845	De Roock W	Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.	The Lancet. Oncology	2010	475
20736745	3845	Irahara N	NRAS mutations are rare in colorectal cancer.	Diagnostic molecular pathology 	2010	43
20927778	3845	Nosho K	Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review.	The Journal of pathology	2010	104
21228335	3845	Bokemeyer C	Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.	Annals of oncology 	2011	163
21239505	3845	Tie J	KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer.	Clinical cancer research 	2011	47
21305640	3845	Vaughn CP	Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer.	Genes, chromosomes and cancer	2011	59
21383284	3845	Hutchins G	Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer.	Journal of clinical oncology 	2011	125
21519026	3845	Bekaii-Saab T	Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers.	Journal of clinical oncology 	2011	60
21632860	3845	Molinari F	Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer.	Clinical cancer research 	2011	56
21943101	3845	Makrodouli E	BRAF and RAS oncogenes regulate Rho GTPase pathways to mediate migration and invasion properties in human colon cancer cells: a comparative study.	Molecular cancer	2011	36
21985784	3845	Ebi H	Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers.	The Journal of clinical investigation	2011	63
22228631	3845	Spindler KL	Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan.	Clinical cancer research 	2012	44
22282465	3845	Miranda C	KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors.	Clinical cancer research 	2012	38
22314188	3845	Pai RK	BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features.	The American journal of surgical pathology	2012	35
22446022	3845	Bokemeyer C	Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials.	European journal of cancer	2012	123
22473155	3845	Tveit KM	Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study.	Journal of clinical oncology 	2012	106
22481281	3845	Chang DT	Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma: an adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic features.	Modern pathology 	2012	33
22665543	3845	Vakiani E	Comparative genomic analysis of primary versus metastatic colorectal carcinomas.	Journal of clinical oncology 	2012	67
22753589	3845	Imamura Y	Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers.	Clinical cancer research 	2012	62
22798500	3845	Tian S	A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction.	Gut	2013	26
23295441	3845	Sia D	Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.	Gastroenterology	2013	61
23348904	3845	Rosty C	Colorectal carcinomas with KRAS mutation are associated with distinctive morphological and molecular features.	Modern pathology 	2013	47
23374602	3845	Pentheroudakis G	Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes.	BMC cancer	2013	33
23511557	3845	Phipps AI	KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers.	British journal of cancer	2013	40
23614898	3845	Morris EJ	Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.	Cancer discovery	2013	94
23660947	3845	Eklöf V	The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer.	British journal of cancer	2013	38
23725851	3845	Seymour MT	Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial.	The Lancet. Oncology	2013	65
23792451	3845	Ogino S	Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology.	Oncogene	2014	38
24018645	3845	Vauthey JN	RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases.	Annals of surgery	2013	29
24024839	3845	Douillard JY	Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.	The New England journal of medicine	2013	383
24042191	3845	Mouradov D	Survival in stage II/III colorectal cancer is independently predicted by chromosomal and microsatellite instability, but not by specific driver mutations.	The American journal of gastroenterology	2013	27
24385213	3845	Tahara T	Fusobacterium in colonic flora and molecular features of colorectal carcinoma.	Cancer research	2014	46
24658074	3845	Thierry AR	Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA.	Nature medicine	2014	70
24687927	3845	Yoon HH	KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance).	Clinical cancer research 	2014	22
25280443	3845	Phipps AI	Association between molecular subtypes of colorectal cancer and patient survival.	Gastroenterology	2015	75
25361982	3845	Klingbiel D	Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial.	Annals of oncology 	2015	20
26216840	3845	Carethers JM	Genetics and Genetic Biomarkers in Sporadic Colorectal Cancer.	Gastroenterology	2015	32
26608120	3845	Johnson DB	Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms.	European journal of cancer	2015	18
23668556	3958	Xing M	Progress in molecular-based management of differentiated thyroid cancer.	Lancet	2013	73
25433395	4286	Hartman ML	MITF in melanoma: mechanisms behind its expression and activity.	Cellular and molecular life sciences 	2015	20
26977879	4286	Smith MP	Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy.	Cancer cell	2016	17
15342696	4292	Domingo E	BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing.	Journal of medical genetics	2004	77
22302899	4292	Sinicrope FA	Molecular pathways: microsatellite instability in colorectal cancer: prognostic, predictive, and therapeutic implications.	Clinical cancer research 	2012	50
23049789	4292	Antelo M	A high degree of LINE-1 hypomethylation is a unique feature of early-onset colorectal cancer.	PloS one	2012	36
18679422	4609	Zhuang D	C-MYC overexpression is required for continuous suppression of oncogene-induced senescence in melanoma cells.	Oncogene	2008	52
23288408	4763	Whittaker SR	A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition.	Cancer discovery	2013	79
26214590	4763	Krauthammer M	Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas.	Nature genetics	2015	40
14695152	4893	Omholt K	NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression.	Clinical cancer research 	2003	84
17119447	4893	Edlundh-Rose E	NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing.	Melanoma research	2006	78
18615679	4893	Agaram NP	Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors.	Genes, chromosomes and cancer	2008	64
20975100	4893	Ellerhorst JA	Clinical correlates of NRAS and BRAF mutations in primary human melanoma.	Clinical cancer research 	2011	49
21107323	4893	Nazarian R	Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.	Nature	2010	594
21166657	4893	Lee JH	Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis.	The British journal of dermatology	2011	68
21615881	4893	Devitt B	Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma.	Pigment cell and melanoma research	2011	52
21880806	4893	Nikiforov YE	Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples.	The Journal of clinical endocrinology and metabolism	2011	95
22048237	4893	Kirkwood JM	Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.	Clinical cancer research 	2012	76
22130161	4893	Joseph RW	Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma.	Journal of immunotherapy	2012	32
22180178	4893	Jakob JA	NRAS mutation status is an independent prognostic factor in metastatic melanoma.	Cancer	2012	97
22614978	4893	Colombino M	BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma.	Journal of clinical oncology 	2012	72
22931913	4893	Mann GJ	BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in patients with stage III melanoma.	The Journal of investigative dermatology	2013	33
23392294	4893	Kinsler VA	Multiple congenital melanocytic nevi and neurocutaneous melanosis are caused by postzygotic mutations in codon 61 of NRAS.	The Journal of investigative dermatology	2013	31
23406027	4893	Ho AL	Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.	The New England journal of medicine	2013	83
23414587	4893	Ascierto PA	MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.	The Lancet. Oncology	2013	129
23515407	4893	Ohashi K	Characteristics of lung cancers harboring NRAS mutations.	Clinical cancer research 	2013	30
23833303	4893	Mar VJ	BRAF/NRAS wild-type melanomas have a high mutation load correlating with histologic and molecular signatures of UV damage.	Clinical cancer research 	2013	29
25148578	4893	Siroy AE	Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma.	The Journal of investigative dermatology	2015	17
25180764	4893	Fedorenko IV	Beyond BRAF: where next for melanoma therapy?	British journal of cancer	2015	28
26095797	4893	Tsao SC	Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations.	Scientific reports	2015	18
26673799	4893	Krepler C	Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies.	Clinical cancer research 	2016	18
21125679	5156	Antonescu CR	The GIST paradigm: lessons for other kinase-driven cancers.	The Journal of pathology	2011	35
23623056	5156	Joensuu H	Gastrointestinal stromal tumour.	Lancet	2013	55
16288007	5290	García-Rostán G	Mutation of the PIK3CA gene in anaplastic thyroid cancer.	Cancer research	2005	81
17314276	5290	Hollestelle A	Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines.	Molecular cancer research 	2007	106
18757405	5290	Yamamoto H	PIK3CA mutations and copy number gains in human lung cancers.	Cancer research	2008	140
19223544	5290	Sartore-Bianchi A	PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.	Cancer research	2009	197
19349352	5290	Kuo KT	Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma.	The American journal of pathology	2009	89
21829508	5290	Janku F	PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers.	PloS one	2011	60
22271473	5290	Janku F	PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations.	Journal of clinical oncology 	2012	145
22285706	5290	Sood A	PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer.	Clinical colorectal cancer	2012	33
22357840	5290	Liao X	Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review.	Clinical cancer research 	2012	88
23094721	5290	Liao X	Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival.	The New England journal of medicine	2012	204
23248156	5290	Janku F	PIK3CA mutations in advanced cancers: characteristics and outcomes.	Oncotarget	2012	30
23785428	5290	Rosty C	PIK3CA activating mutation in colorectal carcinoma: associations with molecular features and survival.	PloS one	2013	31
24218517	5290	Karapetis CS	PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer--results from NCIC CTG/AGITG CO.17.	Clinical cancer research 	2014	25
24533074	5290	Wang L	PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup.	PloS one	2014	25
26392102	5290	Corcoran RB	Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.	Journal of clinical oncology 	2015	48
19318445	5468	Nikiforov YE	Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules.	The Journal of clinical endocrinology and metabolism	2009	103
20099311	5468	Ohori NP	Contribution of molecular testing to thyroid fine-needle aspiration cytology of "follicular lesion of undetermined significance/atypia of undetermined significance".	Cancer cytopathology	2010	41
23302800	5594	Das Thakur M	Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance.	Nature	2013	155
24586666	5594	Umemura M	Store-operated Ca2+ entry (SOCE) regulates melanoma proliferation and cell migration.	PloS one	2014	22
26352686	5594	Tiacci E	Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia.	The New England journal of medicine	2015	19
16439621	5604	Rodriguez-Viciana P	Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome.	Science	2006	127
18632602	5604	Marks JL	Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.	Cancer research	2008	58
20179232	5604	Banerji U	The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer.	Clinical cancer research 	2010	55
21383288	5604	Wagle N	Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.	Journal of clinical oncology 	2011	263
23248257	5604	Kim KB	Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.	Journal of clinical oncology 	2013	83
23587417	5604	Akinleye A	MEK and the inhibitors: from bench to bedside.	Journal of hematology and oncology	2013	65
25202140	5604	Chakraborty R	Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis.	Blood	2014	35
26105199	5604	Kemper K	Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenografts.	EMBO molecular medicine	2015	22
17652623	5609	Wang YF	Apoptosis induction in human melanoma cells by inhibition of MEK is caspase-independent and mediated by the Bcl-2 family members PUMA, Bim, and Mcl-1.	Clinical cancer research 	2007	71
20802351	5609	Hainsworth JD	A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens.	Journal of thoracic oncology 	2010	45
22663011	5609	Flaherty KT	Improved survival with MEK inhibition in BRAF-mutated melanoma.	The New England journal of medicine	2012	379
22805292	5609	Falchook GS	Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.	The Lancet. Oncology	2012	105
23020132	5609	Flaherty KT	Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.	The New England journal of medicine	2012	534
24080641	5609	Jang S	Treatment of BRAF-mutant melanoma: the role of vemurafenib and other therapies.	Clinical pharmacology and therapeutics	2014	23
25037139	5609	Ribas A	Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study.	The Lancet. Oncology	2014	33
25265492	5609	Long GV	Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.	The New England journal of medicine	2014	184
25265494	5609	Larkin J	Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.	The New England journal of medicine	2014	196
25287827	5609	Johnson DB	Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor.	Journal of clinical oncology 	2014	37
25399551	5609	Robert C	Improved overall survival in melanoma with combined dabrafenib and trametinib.	The New England journal of medicine	2015	237
26115796	5609	Ribas A	Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.	The Lancet. Oncology	2015	136
27283860	5609	Planchard D	Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.	The Lancet. Oncology	2016	17
21725359	5728	Xing F	Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF.	Oncogene	2012	60
15035987	5894	Wan PT	Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.	Cell	2004	524
15247181	5928	Kambara T	BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum.	Gut	2004	144
20197478	5928	Dahlin AM	The role of the CpG island methylator phenotype in colorectal cancer prognosis depends on microsatellite instability screening status.	Clinical cancer research 	2010	75
24585723	5928	Goldstein J	Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H).	Annals of oncology 	2014	30
12670889	5979	Kimura ET	High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma.	Cancer research	2003	259
12881714	5979	Soares P	BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC.	Oncogene	2003	101
20130073	5979	Cantara S	Impact of proto-oncogene mutation detection in cytological specimens from thyroid nodules improves the diagnostic accuracy of cytology.	The Journal of clinical endocrinology and metabolism	2010	51
21878896	5979	Nikiforov YE	Molecular genetics and diagnosis of thyroid cancer.	Nature reviews. Endocrinology	2011	126
24248188	5979	Jung CK	The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations.	The Journal of clinical endocrinology and metabolism	2014	49
23766237	7015	Liu X	Highly prevalent TERT promoter mutations in aggressive thyroid cancers.	Endocrine-related cancer	2013	68
23887589	7015	Vinagre J	Frequency of TERT promoter mutations in human cancers.	Nature communications	2013	120
24141777	7015	Liu T	The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas.	Oncogene	2014	43
24569790	7015	Heidenreich B	Telomerase reverse transcriptase promoter mutations in primary cutaneous melanoma.	Nature communications	2014	24
25217772	7015	Griewank KG	TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma.	Journal of the National Cancer Institute	2014	30
26579470	10018	Huang L	Mechanisms of resistance to EGFR tyrosine kinase inhibitors.	Acta pharmaceutica Sinica. B	2015	29
25851630	10156	Normanno N	Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial.	Annals of oncology 	2015	23
23104212	10178	Roth AD	Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer.	Journal of the National Cancer Institute	2012	45
25665005	10413	Lin L	The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.	Nature genetics	2015	62
24296758	10568	Aisner DL	ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers.	Molecular cancer research 	2014	30
12438234	22882	Yuen ST	Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia.	Cancer research	2002	95
12692057	22882	Tannapfel A	Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma.	Gut	2003	92
15781657	22882	Sharma A	Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors.	Cancer research	2005	94
16273091	22882	Solit DB	BRAF mutation predicts sensitivity to MEK inhibition.	Nature	2006	370
17208430	22882	Dhomen N	New insight into BRAF mutations in cancer.	Current opinion in genetics and development	2007	67
18390968	22882	Adjei AA	Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.	Journal of clinical oncology 	2008	161
18559533	22882	Montagut C	Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma.	Cancer research	2008	145
19915144	22882	Emery CM	MEK1 mutations confer resistance to MEK and B-RAF inhibition.	Proceedings of the National Academy of Sciences of the United States of America	2009	170
19933846	22882	Ritt DA	Impact of feedback phosphorylation and Raf heterodimerization on normal and mutant B-Raf signaling.	Molecular and cellular biology	2010	51
20538618	22882	Whittaker S	Gatekeeper mutations mediate resistance to BRAF-targeted therapies.	Science translational medicine	2010	59
20668238	22882	Joseph EW	The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner.	Proceedings of the National Academy of Sciences of the United States of America	2010	149
20818433	22882	Kaplan FM	Hyperactivation of MEK-ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells.	Oncogene	2011	44
21441104	22882	Hu J	Mutation that blocks ATP binding creates a pseudokinase stabilizing the scaffolding function of kinase suppressor of Ras, CRAF and BRAF.	Proceedings of the National Academy of Sciences of the United States of America	2011	39
21803746	22882	Shi H	Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition.	Cancer research	2011	64
22113612	22882	Poulikakos PI	RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).	Nature	2011	347
22402123	22882	Hatzivassiliou G	ERK inhibition overcomes acquired resistance to MEK inhibitors.	Molecular cancer therapeutics	2012	48
23134356	22882	Callahan MK	Progression of RAS-mutant leukemia during RAF inhibitor treatment.	The New England journal of medicine	2012	57
23489023	22882	Kim KB	Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation.	Thyroid 	2013	43
24202393	22882	Lito P	Tumor adaptation and resistance to RAF inhibitors.	Nature medicine	2013	130
24265153	22882	Van Allen EM	The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.	Cancer discovery	2014	157
24265154	22882	Wagle N	MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.	Cancer discovery	2014	109
24823863	22882	Levy JM	Autophagy inhibition improves chemosensitivity in BRAF(V600E) brain tumors.	Cancer discovery	2014	31
24957944	22882	Holderfield M	Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond.	Nature reviews. Cancer	2014	110
25324352	22882	Hyman DM	Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders.	Cancer discovery	2015	27
26466569	22882	Zhang C	RAF inhibitors that evade paradoxical MAPK pathway activation.	Nature	2015	28
26566875	22882	Diamond EL	Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.	Cancer discovery	2016	21
25399552	29126	Robert C	Nivolumab in previously untreated melanoma without BRAF mutation.	The New England journal of medicine	2015	461
25736262	29126	Johnson DB	Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies.	Cancer immunology research	2015	21
26181250	29126	Larkin J	Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.	JAMA oncology	2015	25
27196573	29126	Masugi Y	Tumour CD274 (PD-L1) expression and T cells in colorectal cancer.	Gut	2017	8
22157620	57670	Lin A	BRAF alterations in primary glial and glioneuronal neoplasms of the central nervous system with identification of 2 novel KIAA1549:BRAF fusion variants.	Journal of neuropathology and experimental neurology	2012	39
22343534	100271849	Lohr JG	Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing.	Proceedings of the National Academy of Sciences of the United States of America	2012	240
